The latest drugs create new challenges for our analysts and formulators as they tend have reduced solubility and stability. We’ve certainly enjoyed working alongside our biotech clients to address some of the issues. They are at the forefront of innovation which makes for exciting projects.
Some clients want a hands-on approach – they often work alongside our scientists in dedicated project rooms that protect their confidentiality. It’s valuable to discuss what’s required right from the start.
Before we launch into drug development it’s important to keep in mind what we’re trying to achieve. At the early stage you don’t necessarily need a perfect method, just one that is fit for purpose. This can save considerable time and expense.
One thing we know from the start is that biotechnology products will need to go to the regulators at some stage, and early-stage analysis can help create a data portfolio that adds value and provides confidence during licensing negotiations.
There’s a temptation for biotech companies to dismiss traditional techniques, but we often give the advice that these approaches are the best choice. Although we offer a range of analyses we often find that conventional techniques such as High Performance Liquid Chromatography (HPLC) produce all the information that’s needed. They have a broad range of applicability and are reliable even with smaller biomolecules.
Other facilities include a formulation suite with support for lab-scale manufacture, support for novel device development including inhalers and nebulisers, and extended stability storage and test rooms.
